Soluble LDL-Immune Complexes in Type 2 Diabetes and Vascular Disease

2002 ◽  
Vol 34 (4) ◽  
pp. 196-201 ◽  
Author(s):  
Z. Turk ◽  
M. Šesto ◽  
J. Skodlar ◽  
G. Ferenčak ◽  
N. Turk ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Vascular Disease ◽  
Immune Complexes

scholarly journals The Relation Between HbA1cand Cardiovascular Events in Patients With Type 2 Diabetes With and Without Vascular Disease

Diabetes Care ◽  
2015 ◽  
Vol 38 (10) ◽  
pp. 1930-1936 ◽  
Author(s):  
Guido Kranenburg ◽  
Yolanda van der Graaf ◽  
Joep van der Leeuw ◽  
Hendrik M.W. Nathoe ◽  
Gert Jan de Borst ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Vascular Disease ◽  
Cardiovascular Events

scholarly journals HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease

2014 ◽  
Vol 24 (6) ◽  
pp. 594-599 ◽  
Author(s):  
C. Morgantini ◽  
D. Meriwether ◽  
S. Baldi ◽  
E. Venturi ◽  
S. Pinnola ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Vascular Disease ◽  
Lipid Composition ◽  
Atherosclerotic Vascular Disease

Cardiovascular Risk in Type 2 Diabetes – Reflecting on the ADVANCE Study

2009 ◽  
Vol 05 (0) ◽  
pp. 42
Author(s):  
Sophia Zoungas ◽  
John Chalmers ◽  
Anushka Patel ◽  
◽  
◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Vascular Disease ◽  
Large Scale ◽  
Intensive Glucose Control ◽  
Vascular Events ◽  
Advance Study ◽  
High Blood Glucose

The world is facing an unprecedented increase in type 2 diabetes. Most disability and premature mortality experienced by patients with diabetes is related to vascular disease and, in particular, macrovascular disease (such as coronary heart disease and stroke) and microvascular disease (such as retinopathy, nephropathy and neuropathy). Indeed, around 1.9 million cardiovascular deaths worldwide are attributable to high blood glucose levels and diabetes, as well as to their associated dangerous companions of high blood pressure and abnormal lipid levels. The global economic costs of diabetes, including foregone economic growth and increasing healthcare expenditure, are substantial and are anticipated to grow. Therefore, strategies to reduce disease burden have continued to focus on reducing cardiovascular risk. Recently, a number of large-scale clinical trials have evaluated approaches for managing cardiovascular risk in patients with type 2 diabetes. Among them the Action in Diabetes and Vascular Disease: PreterAx and DiamicroN MR Controlled Evaluation (ADVANCE) trial has reported the effects of blood pressure lowering and intensive glucose control on major vascular events in patients with established type 2 diabetes. In this article we summarise the findings of the ADVANCE trial and discuss its relevance to the management of cardiovascular risk in patients with type 2 diabetes worldwide.

Cardiovascular Risk in Type 2 Diabetes – Reflecting on the ADVANCE Study

2009 ◽  
Vol 05 (01) ◽  
pp. 42
Author(s):  
Sophia Zoungas ◽  
John Chalmers ◽  
Anushka Patel ◽  
◽  
◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Vascular Disease ◽  
Large Scale ◽  
Intensive Glucose Control ◽  
Vascular Events ◽  
Advance Study ◽  
High Blood Glucose

The world is facing an unprecedented increase in type 2 diabetes. Most disability and premature mortality experienced by patients with diabetes is related to vascular disease and, in particular, macrovascular disease (such as coronary heart disease and stroke) and microvascular disease (such as retinopathy, nephropathy and neuropathy). Indeed, around 1.9 million cardiovascular deaths worldwide are attributable to high blood glucose levels and diabetes, as well as to their associated dangerous companions of high blood pressure and abnormal lipid levels. The global economic costs of diabetes, including foregone economic growth and increasing healthcare expenditure, are substantial and are anticipated to grow. Therefore, strategies to reduce disease burden have continued to focus on reducing cardiovascular risk. Recently, a number of large-scale clinical trials have evaluated approaches for managing cardiovascular risk in patients with type 2 diabetes. Among them the Action in Diabetes and Vascular Disease: PreterAx and DiamicroN MR Controlled Evaluation (ADVANCE) trial has reported the effects of blood pressure lowering and intensive glucose control on major vascular events in patients with established type 2 diabetes. In this article we summarise the findings of the ADVANCE trial and discuss its relevance to the management of cardiovascular risk in patients with type 2 diabetes worldwide.

Sign in / Sign up

Export Citation Format

Share Document